Late Friday, the FDA approved Gilead Sciences' much awaited hepatitis C treatment Sovaldi. How will Gilead shares react in the coming weeks?
Eli Lilly is facing a perfect storm. Its lead product, the antidepressant Cymbalta will lose its U.S. patent exclusivity this week while its late stage phase 3 wildcating has been producing dry holes.
Orexigen Therapeutics announces successful interim results for its lead product candidate Contrave followed by the potentially share dilutive announcement of $100 million convertible senior notes offering. Which way should the stock go?
Celgene, which has almost doubled in value since the begining of the year, reported a strong 3rd quarter performance, raised its EPS guidance for the year and is poised for another exceptional year in 2014.
Let's dive deeper at Salix Pharmaceuticals' acquisition of Santarus and its lead drug Uceris.
Seattle Genetics share price has been trending lower lately due to adverse side effects experienced by some patients undergoing clinical trials with the company’s lead product Adcetris. Since long term prospects look bright forSeattle, this could be a nice chance for value investors to enter the stock.
Regeneron's Eylea U.S. sales are expected to reach $1.3 billion in 2013, qualifying it for a blockbuster status after just two full years on the market.